Raj Rajendran

Title: Raj Rajendran: Innovator in mRNA Therapy for Phenylketonuria

Introduction

Raj Rajendran is a notable inventor based in Sharon, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of mRNA therapies. His work focuses on addressing genetic disorders, specifically phenylketonuria (PKU), a condition that affects the metabolism of phenylalanine.

Latest Patents

Raj Rajendran holds a patent for "Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria." This innovative disclosure relates to mRNA therapy aimed at treating hyperphenylalaninemias such as PKU. The mRNAs developed in this invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH) and its functional fragments. These mRNAs are preferably encapsulated in lipid nanoparticles (LNPs) to ensure efficient delivery to cells and tissues. The therapies increase and restore deficient levels of PAH expression and activity, thereby reducing the abnormal accumulation of phenylalanine in affected individuals.

Career Highlights

Raj Rajendran is currently associated with Modernatx, Inc., where he continues to advance his research in mRNA technology. His work has the potential to transform treatment options for individuals suffering from PKU and similar metabolic disorders.

Collaborations

Some of his notable coworkers include Paolo G V Martini and Patrick Finn, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Raj Rajendran's innovative work in mRNA therapy represents a significant advancement in the treatment of phenylketonuria. His contributions are paving the way for new therapeutic approaches that could greatly benefit patients with metabolic disorders.